StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Tuesday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

TXMD stock opened at $1.59 on Tuesday. TherapeuticsMD has a one year low of $1.43 and a one year high of $3.07. The firm has a 50-day simple moving average of $1.69 and a two-hundred day simple moving average of $1.82.

TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.23 million for the quarter.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC bought a new position in TherapeuticsMD, Inc. (NASDAQ:TXMD) in the first quarter, according to its most recent filing with the SEC. The firm bought 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned approximately 0.21% of TherapeuticsMD as of its most recent SEC filing. 30.74% of the stock is owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.